## Anti-prothrombin autoantibodies enriched after infecti by strength of antibody response against SARS-CoV-2 p

PLoS Pathogens 17, e1010118 DOI: 10.1371/journal.ppat.1010118

**Citation Report** 

#	Article	IF	CITATIONS
2	COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses, 2021, 13, 1594.	3.3	31
4	Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma. Life Science Alliance, 2022, 5, e202101270.	2.8	24
5	Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmunity Reviews, 2022, 21, 103012.	5.8	60
9	Lack of association between pandemic chilblains and SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	18
10	Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2. ACS Infectious Diseases, 2022, 8, 790-799.	3.8	8
11	Autoantibodies in COVIDâ€19 correlate with antiviral humoral responses and distinct immune signatures. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2415-2430.	5.7	32
13	The pathogenesis of neurologic symptoms of the postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. Current Opinion in Neurology, 2022, 35, 384-391.	3.6	8
14	Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants. IScience, 2022, 25, 104766.	4.1	13
15	Complementary Sets of Autoantibodies Induced by SARS-CoV-2, Adenovirus and Bacterial Antigens Cross-React with Human Blood Protein Antigens in COVID-19 Coagulopathies. International Journal of Molecular Sciences, 2022, 23, 11500.	4.1	6
16	COVID-19 and antiphospholipid antibodies. Best Practice and Research in Clinical Haematology, 2022, 35, 101402.	1.7	12
17	Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. Scientific Reports, 2022, 12, .	3.3	2
18	The role of the intestinal microbiome in antiphospholipid syndrome. Frontiers in Immunology, 0, 13, .	4.8	3
19	The relationship between chronic immune response and neurodegenerative damage in long COVID-19. Frontiers in Immunology, 0, 13, .	4.8	11
20	TLR7 and IgM: Dangerous Partners in Autoimmunity. Antibodies, 2023, 12, 4.	2.5	2
21	Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region. IScience, 2023, 26, 105928.	4.1	5
22	Aged brain and neuroimmune responses to COVID-19: post-acute sequelae and modulatory effects of behavioral and nutritional interventions. Immunity and Ageing, 2023, 20, .	4.2	3
23	From Co-Infections to Autoimmune Disease via Hyperactivated Innate Immunity: COVID-19 Autoimmune Coagulopathies, Autoimmune Myocarditis and Multisystem Inflammatory Syndrome in Children. International Journal of Molecular Sciences, 2023, 24, 3001.	4.1	12
24	Protocol to determine antibody affinity and concentration in complex solutions using microfluidic antibody affinity profiling. STAR Protocols, 2023, 4, 102095.	1.2	2

#	Article	IF	CITATIONS
25	A Molecular Biomarker-Based Triage Approach for Targeted Treatment of Post-COVID-19 Syndrome Patients with Persistent Neurological orÂNeuropsychiatric Symptoms. Advances in Experimental Medicine and Biology, 2023, , 97-115.	1.6	3
26	The immunology of long COVID. Nature Reviews Immunology, 2023, 23, 618-634.	22.7	70
27	Antiphospholipid antibodies are enriched post-acute COVID-19 but do not modulate the thrombotic risk. Clinical Immunology, 2023, 257, 109845.	3.2	0
29	Prothrombin changes and suggested correlation with the titers of anti-SARS-CoV-2 IgG antibodies in recently recovered from SARS-CoV-2 infection healthy volunteers. Minerva Biotechnology and Biomolecular Research, 2024, 36, .	0.5	0